Meeting
2022 ASCO Annual Meeting
IMPemBra, a phase 2 study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation: Three-year survival data and translational analyses.
Authors
Elisa A. Rozeman
Netherlands Cancer Institute, Amsterdam, Netherlands
Elisa A. Rozeman , Judith M. Versluis , Esmée P Hoefsmit , Petros Dimitriadis , Lindsay G. Grijpink-Ongering , Karolina Sikorska , Bart A. van de Wiel , Birthe C Heeres , Claudi Flohil , Pia Kvistborg , Daan van den Broek , Annegien Broeks , Jan Willem de Groot , Sofie Wilgenhof , Marieke A. Vollebergh , Johannes V. van Thienen , John B. A. G. Haanen , Christian U. Blank
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02625337
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9552)
DOI
10.1200/JCO.2022.40.16_suppl.9552
Abstract #
9552
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.
First Author: Elisa A. Rozeman
Poster
2016 ASCO Annual Meeting
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
First Author: Georgina V. Long
Poster
2015 ASCO Annual Meeting
SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma.
First Author: Alain Patrick Algazi
Poster
2022 ASCO Annual Meeting
A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).
First Author: Nicholas Coupe